Encapsulated Vaccines Against Select Agents

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,957.00
Award Year:
2008
Program:
STTR
Phase:
Phase I
Contract:
1R41AI068252-01A2
Award Id:
89466
Agency Tracking Number:
AI068252
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
NANORELEASE TECHNOLOGIES, LLC, 5013 CONGRESSIONAL CT, COLLEGE STATION, TX, 77845
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
192756984
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The ultimate goal of the research proposed is the development of vaccines against intracellular pathogens. The model system to be employed is the Brucella spp, a causative agent of infectious abortion in animals (Bang' s disease) and undulant fever, a chronic debilitating disease in humans. Historically, elimination of brucellosis as a public health threat has relied on the elimination of animal infection. However, the potential threat of bioterrorism or biowarfare use of this class B select agent underscores the need to develop direct intervention strategies to preserve public health. The long range goal is to develop an enabling technology for the enhancement and delivery of promising vaccines through controlled relea se. The objectives of this application are to entrap live, highly attenuated vaccine strains, in specialized coatings designed for controlled release, and test their efficacy in a mouse model. We propose that the use of controlled release vehicles can pote ntiate the use of safe but moderately protective strains and produce efficacious, marketable vaccines. We have several lines of strong preliminary data to support this work. These include i) Brucella attenuated strains developed through specific mutagene sis and characterized with regard to safety and efficacy in a mouse model and, ii) vaccination data documenting the performance of novel proteins as a robust erodible biopolymer in vaccine delivery systems. We will test our hypothesis with the following sp ecific aims: 1) Entrap target strains in capsule formulations enabling sustained release and 2) Test the safety and efficacy of these novel encapsulated strains in a mouse model.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government